» Articles » PMID: 28856910

Distribution of CGRP and CGRP Receptor Components in the Rat Brain

Overview
Journal Cephalalgia
Specialties Neurology
Psychiatry
Date 2017 Sep 1
PMID 28856910
Citations 42
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Calcitonin gene-related peptide and its receptor, consisting of receptor activity-modifying protein 1 and calcitonin receptor-like receptor, are of considerable interest because of the role they play in migraine and recently developed migraine therapies.

Methods: To better understand the function of this neuropeptide, we used immunohistochemistry to determine a detailed distribution of calcitonin gene-related peptide, receptor activity-modifying protein 1 and calcitonin receptor-like receptor in the rat brain in a region of 0.5-1.5 mm lateral to the midline. We found calcitonin gene-related peptide immunoreactivity in most of the neurons of the cerebral cortex, hippocampus, cerebellum, thalamic nuclei, hypothalamic nuclei and brainstem nuclei. In contrast, receptor activity-modifying protein 1 and calcitonin receptor-like receptor immunoreactivity were found almost exclusively in the neuronal processes in the investigated regions.

Conclusion: Overall, the degree of expression of calcitonin gene-related peptide and calcitonin gene-related peptide receptor components in the central nervous system is astonishingly complex and suggestive of many different brain functions, including a possible role in migraine. However, currently, the presence of calcitonin gene-related peptide and the nature of its receptors throughout the brain is an enigma yet to be solved.

Citing Articles

Antimicrobial Neuropeptides and Their Receptors: Immunoregulator and Therapeutic Targets for Immune Disorders.

Chen K, Wu X, Li X, Pan H, Zhang W, Shang J Molecules. 2025; 30(3).

PMID: 39942672 PMC: 11820534. DOI: 10.3390/molecules30030568.


Sex differences in expression of CGRP family of receptors and ligands in the rat trigeminal system.

Maddahi A, Edvinsson J, Edvinsson L J Headache Pain. 2024; 25(1):193.

PMID: 39516766 PMC: 11545840. DOI: 10.1186/s10194-024-01893-1.


Pituitary cyclase-activating polypeptide targeted treatments for the treatment of primary headache disorders.

Karsan N, Edvinsson L, Vecsei L, Goadsby P Ann Clin Transl Neurol. 2024; 11(7):1654-1668.

PMID: 38887982 PMC: 11251486. DOI: 10.1002/acn3.52119.


Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy.

Karsan N, Goadsby P CNS Drugs. 2024; 38(7):533-546.

PMID: 38822165 DOI: 10.1007/s40263-024-01091-2.


Mode and site of action of therapies targeting CGRP signaling.

Labastida-Ramirez A, Caronna E, Gollion C, Stanyer E, Dapkute A, Braniste D J Headache Pain. 2023; 24(1):125.

PMID: 37691118 PMC: 10494408. DOI: 10.1186/s10194-023-01644-8.